8-K: BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates

BioAge Labs announces its full year 2024 financial results, highlights pipeline progress, and unveils new platform partnerships with Novartis and Lilly.

Summary

• BioAge Labs reported its full year 2024 financial results and provided business updates for the fourth quarter of 2024.
• The company discontinued the Phase 2 clinical trial for azelaprag due to unexpected liver transaminitis in some patients.
• BioAge is progressing BGE-102, an oral, brain-penetrant NLRP3 inhibitor, with initial Phase 1 data expected in the second half of 2025.
• New research collaborations were established with Novartis and Lilly to discover and develop novel therapies for age-related diseases and metabolic aging.
• Research and development expenses increased to $59.0 million for the year ended December 31, 2024, compared to $33.9 million in 2023.
• General and administrative expenses were $19.2 million for the year ended December 31, 2024, compared to $14.5 million in 2023.
• Net loss was $71.1 million for the year ended December 31, 2024, compared to a net loss of $63.9 million in 2023.
• As of December 31, 2024, BioAge had approximately $354.3 million in cash and cash equivalents, which is expected to fund operations through 2029.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the discontinuation of azelaprag is a setback, the progress of BGE-102, the collaborations with Novartis and Lilly, and the strong cash position provide a positive outlook. The increased net loss and R&D expenses are concerning but balanced by the company's strategic initiatives.

Positives

• BioAge is progressing BGE-102, an oral, brain-penetrant NLRP3 inhibitor, with Phase 1 data expected in 2H25.
• The company has established collaborations with Novartis and Lilly to discover novel targets for therapies addressing age-related diseases and metabolic aging.
• BioAge has a strong cash position of $354.3 million as of December 31, 2024, expected to fund operations through 2029.

Negatives

• BioAge discontinued the Phase 2 clinical trial for azelaprag due to unexpected liver transaminitis.
• The company reported a net loss of $71.1 million for the year ended December 31, 2024, which is higher than the $63.9 million loss in 2023.
• Research and development expenses increased significantly to $59.0 million for the year ended December 31, 2024.

Risks

• The development of BGE-102 and other pipeline candidates is subject to clinical trial risks and regulatory approvals.
• The collaborations with Novartis and Lilly are subject to risks related to achieving milestones and commercializing potential therapies.
• The company's financial performance is subject to risks related to increasing expenses and potential future capital needs.

Future Outlook

BioAge estimates that its existing cash and cash equivalents will be sufficient to fund operations and capital expenses through 2029.

Management Comments

• Kristen Fortney, Ph.D., CEO and co-founder of BioAge, stated that the fourth quarter of 2024 was marked by key strategic decisions and solid pipeline progress.
• She noted the decision to discontinue azelaprag development and the continued progression of chemically distinct APJ agonists.
• She highlighted the accelerated clinical timelines for BGE-102 and the validation of the company's platform through collaborations with Novartis and Lilly.
• She believes the company is well-positioned to execute on its strategy and deliver transformative treatments for metabolic diseases.

Industry Context

BioAge's focus on metabolic diseases and aging aligns with growing interest in therapies targeting age-related conditions. The collaborations with Novartis and Lilly demonstrate the value of BioAge's platform in identifying novel therapeutic targets. The discontinuation of azelaprag highlights the challenges in drug development and the importance of safety.

Comparison to Industry Standards

• The discontinuation of azelaprag due to liver transaminitis is a common issue in drug development, with companies like DILIsym Services offering predictive toxicology services to mitigate such risks.
• BioAge's collaborations with Novartis and Lilly are similar to other biotech partnerships, such as the collaboration between Recursion Pharmaceuticals and Bayer to discover and develop novel therapeutics for fibrotic diseases.
• The company's cash runway through 2029 is relatively long compared to other biotech companies, providing financial stability for its development programs.

Stakeholder Impact

• Shareholders: The discontinuation of azelaprag may negatively impact shareholder value, while the progress of BGE-102 and collaborations with Novartis and Lilly could positively impact shareholder value.
• Employees: The company's strategic initiatives and financial stability provide job security for employees.
• Customers: The development of new therapies for metabolic diseases could benefit patients in need of treatment.
• Partners: The collaborations with Novartis and Lilly provide opportunities for joint development and commercialization of new therapies.

Next Steps

• Advance BGE-102 through IND-enabling experiments and Phase 1 clinical trials.
• Continue development of next-generation APJ agonists.
• Execute research collaborations with Novartis and Lilly to discover novel therapeutic targets.
• Progress preclinical programs leveraging insights from the company's proprietary discovery platform.

Key Dates

Keywords

BioAge Labs, Financial Results, BGE-102, NLRP3 inhibitor, APJ agonists, Novartis, Lilly, Metabolic Diseases, Aging, Clinical Trials